版本:
中国

BRIEF-Foamix Pharmaceuticals announces plans for additional phase 3 trial for FMX101 in moderate to severe acne

May 1 Foamix Pharmaceuticals Ltd:

* Foamix Pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne

* Foamix Pharmaceuticals ltd- commencement of 3(rd) phase 3 trial planned mid 2017; submittal of nda planned in h2-2018

* Foamix pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne

* Foamix pharmaceuticals ltd- pooled analyses of phase 3 data show additional statistically significant effects on primary and secondary efficacy endpoints

* Foamix pharmaceuticals - if results will be positive, trial is expected to form basis for a nda which company plans to submit in second half of 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐